MedTrace Logo

Stereotactic Body Radiotherapy for Patients With Breast Cancer Oligometastasis

NCT03295916 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-01-29

No results posted yet for this study

Summary

The purpose of this study is to evaluate feasibility to treat metachronous multi-site breast cancer oligometastasis with stereotactic body radiotherapy (SBRT) in patients on systemic therapy.

Conditions

Interventions

RADIATION

Stereotactic Body Radiotherapy

Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT

Sponsors & Collaborators

  • Toronto Sunnybrook Regional Cancer Centre

    collaborator OTHER

  • Juravinski Cancer Center

    lead OTHER

Principal Investigators

  • Anand Swaminath, MD,FRCPC · McMaster University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2020-04-01
Completion
2021-04-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03295916 on ClinicalTrials.gov